Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Seidman AD, Hochhauser D, Gollub M, Edelman B, Yao TJ, Hudis CA, Francis P, Fennelly D, Gilewski TA, Moynahan ME, Currie V, Baselga J, Tong W, O'Donaghue M, Salvaggio R, Auguste L, Spriggs D, Norton L. Seidman AD, et al. Among authors: moynahan me. J Clin Oncol. 1996 Jun;14(6):1877-84. doi: 10.1200/JCO.1996.14.6.1877. J Clin Oncol. 1996. PMID: 8656256 Clinical Trial.
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Dang C, Fornier M, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C. Dang C, et al. Among authors: moynahan me. J Clin Oncol. 2008 Mar 10;26(8):1216-22. doi: 10.1200/JCO.2007.12.0733. J Clin Oncol. 2008. PMID: 18323546 Clinical Trial.
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Dang C, Iyengar N, Datko F, D'Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C. Dang C, et al. Among authors: moynahan me. J Clin Oncol. 2015 Feb 10;33(5):442-7. doi: 10.1200/JCO.2014.57.1745. Epub 2014 Dec 29. J Clin Oncol. 2015. PMID: 25547504 Free PMC article. Clinical Trial.
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA. Seidman AD, et al. Among authors: moynahan me. J Clin Oncol. 2001 May 15;19(10):2587-95. doi: 10.1200/JCO.2001.19.10.2587. J Clin Oncol. 2001. PMID: 11352950 Clinical Trial.
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C. Fornier MN, et al. Among authors: moynahan me. Clin Cancer Res. 2001 Dec;7(12):3934-41. Clin Cancer Res. 2001. PMID: 11751485 Clinical Trial.
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
Hudis C, Riccio L, Holmes F, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Moynahan M, Raptis G, Sklarin N, Surbone A, Uhlenhopp M, Maickel N, Yao TJ, Hellmann S, Usakewicz J, Hortobagyi G, Norton L. Hudis C, et al. Eur J Cancer. 1997 Nov;33(13):2198-202. doi: 10.1016/s0959-8049(97)00254-2. Eur J Cancer. 1997. PMID: 9470806 Clinical Trial.
60 results